Related Experiment Videos
Venlafaxine and asthma.
Øyvind Melien1, Tone Skaali, Kirsten Myhr
1Section of Clinical Pharmacology, Rikshospitalet University Hospital, NO-0407, Oslo, Norway. oyvind.melien@rikshospitalet.no
Nordic Journal of Psychiatry
|December 1, 2005
Summary
Venlafaxine, an antidepressant, can cause asthma-like respiratory reactions in some patients. Discontinuing the medication led to the improvement of the patient's breathing difficulties.
Area of Science:
- Pharmacology
- Pulmonology
- Clinical Medicine
Background:
- Major depression is a common psychiatric disorder often treated with antidepressants.
- Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) used for depression.
- Adverse drug reactions can manifest in various organ systems, including the respiratory tract.
Observation:
- A 54-year-old male patient experienced asthma-like symptoms, including nocturnal dry cough and daytime dyspnea, during venlafaxine treatment.
- Symptoms progressively worsened over five weeks of venlafaxine therapy.
- Clinical examination revealed significant pulmonary obstruction, with forced expiratory volume (FEV1) at 32% of the predicted value.
Findings:
- The patient's respiratory symptoms were attributed to a potential adverse reaction to venlafaxine.
- Gradual dose reduction and eventual discontinuation of venlafaxine led to a successive improvement in respiratory complaints.
- This case suggests a possible link between venlafaxine and the development of obstructive respiratory symptoms.
Implications:
- Clinicians should consider venlafaxine as a potential cause of new-onset asthma-like symptoms in patients.
- Pulmonary function testing is crucial for diagnosing and monitoring such adverse reactions.
- Further investigation into the mechanisms of venlafaxine-induced respiratory effects may be warranted.